News und Analysen

Zimmer Biomet Holdings, a leading medical technology manufacturer specializing in orthopedics, has announced a dividend distribution of $0.24 per share scheduled for late March 2025. This payment

Eli Lilly's experimental drug Lepodisiran has delivered impressive results in Phase 2 clinical trials, reducing a genetic risk factor for heart disease by nearly 94 percent. The drug targets

Abbott Laboratories recently experienced a significant upward breakthrough after receiving CE marking for its innovative Volt PFA system, designed to treat atrial fibrillation. This heart rhythm

Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical

Eli Lilly's stock has demonstrated remarkable resilience this year, gaining approximately 6% while Danish competitor Novo Nordisk faced significant losses. This divergence in performance reflects a

Merck & Co. has entered a landmark licensing agreement with Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral inhibitor targeting lipoprotein(a) formation for

AbbVie is experiencing a slight downturn in the stock market, with shares currently trading at $209.96, representing a 0.94 percent decline. The pharmaceutical giant's stock dropped by $2.00

Die Bristol-Myers Squibb Aktie zeigt sich derzeit in solider Verfassung. Der Kurs des Biopharmazie-Riesen kletterte auf 61,04 USD (Stand: 22. März 2025), was einem Anstieg von 1,01% zum Vortag

Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous

Alnylam Pharmaceuticals has secured a significant victory with the FDA's approval to expand Amvuttra's (vutrisiran) use for treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare and

Biomarin Pharmaceutical recently presented compelling new data for its key medications VOXZOGO and PALYNZIQ at the American College of Medical Genetics and Genomics annual meeting, sparking investor

In March 2025, several top executives at healthcare company Evolus sold significant portions of their company shares through pre-established 10b5-1 trading plans. Director David Moatazedi divested

Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears

Executives at molecular diagnostics company Natera have recently sold shares worth over $1.2 million, even as the company demonstrates impressive market performance. Board Chairman Matthew

ANI Pharmaceuticals, a diversified biopharmaceutical company valued at $1.3 billion, has announced the launch of 500mg Nitazoxanide tablets, a generic version of reference drug Alinia®. This

Quest Diagnostics, a leading provider of diagnostic information services, experienced a significant 4.75% decline on the New York Stock Exchange following disappointing long-term growth projections

Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per

ANI Pharmaceuticals has made a significant financial move that could substantially improve its future prospects. The pharmaceutical company announced the complete elimination of its royalty

Eli Lilly faces a potential challenge to its dominant position in the lucrative GLP-1 market after Lexaria Bioscience Corp. reported breakthrough results with its oral DehydraTECH-tirzepatide